Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $575.00

Intuitive Surgical (NASDAQ:ISRG) had its target price increased by JPMorgan Chase & Co. from $495.00 to $575.00 in a research report released on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the medical equipment provider’s stock.

Other equities analysts also recently issued reports about the stock. Robert W. Baird boosted their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an outperform rating in a research note on Friday, July 19th. Evercore ISI upped their price objective on Intuitive Surgical from $410.00 to $475.00 and gave the stock an in-line rating in a report on Tuesday, October 1st. Truist Financial increased their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the company a buy rating in a research report on Tuesday, July 16th. Royal Bank of Canada boosted their target price on Intuitive Surgical from $515.00 to $525.00 and gave the stock an outperform rating in a research report on Tuesday, October 8th. Finally, BTIG Research raised their price target on Intuitive Surgical from $469.00 to $494.00 and gave the company a buy rating in a report on Wednesday, August 28th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $458.35.

Intuitive Surgical Price Performance

Shares of ISRG opened at $484.78 on Friday. The company has a market capitalization of $171.95 billion, a P/E ratio of 87.51, a PEG ratio of 5.40 and a beta of 1.39. Intuitive Surgical has a one year low of $254.85 and a one year high of $496.48. The business’s 50 day simple moving average is $480.34 and its 200-day simple moving average is $435.19.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the previous year, the firm earned $1.18 earnings per share. The business’s revenue was up 14.5% on a year-over-year basis. On average, sell-side analysts anticipate that Intuitive Surgical will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the sale, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now owns 821 shares of the company’s stock, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares in the company, valued at $145,113.45. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,120 shares of company stock valued at $25,528,753. Company insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Mirador Capital Partners LP grew its holdings in shares of Intuitive Surgical by 1.4% in the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock valued at $1,732,000 after acquiring an additional 50 shares in the last quarter. Advisors Asset Management Inc. increased its position in shares of Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after purchasing an additional 1,129 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of Intuitive Surgical by 5.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after purchasing an additional 9,869 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Intuitive Surgical by 617.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock valued at $39,622,000 after buying an additional 76,649 shares in the last quarter. Finally, SWP Financial LLC acquired a new position in Intuitive Surgical during the fourth quarter worth $255,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.